Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Efavirenz for Patients With Alzheimer's Disease

This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment

mild cognitive impairment
neuropsychological test
cognitive impairment
cognitive decline
dementia
  • 1 views
  • 28 Jan, 2021
  • 1 location
HIV Antiretroviral Drugs and Metabolism

improvement in flow mediated vasodilation and circulating markers of endothelial function Protocol 2A: The effects of efavirenz on HDL composition, HDL function, apo AI production, apo AI clearance

efavirenz
lopinavir/ritonavir
ritonavir
antiretroviral agents
lopinavir
  • 6 views
  • 07 Nov, 2020
  • 1 location
DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa

reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.

  • 0 views
  • 26 Jan, 2021
  • 2 locations
PI Vs. NNRTI Based Therapy for HIV Advanced Disease

Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy naïve and initiate therapy with CD4 counts ≤ 200/mm3.

efavirenz
zidovudine
antiretroviral agents
lopinavir
lopinavir/ritonavir
  • 32 views
  • 07 Nov, 2020
  • 5 locations
Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)

explored in HIV-infected pregnant women on daily CTX in Uganda. Unfortunately, the study was inconclusive because malaria transmission was too low and a clinically relevant drug interaction with efavirenz

  • 0 views
  • 23 Jan, 2021
  • 1 location
Once Daily 3TC Efavirenz and ddI for HIV Infection

Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to assess compliance with a once-daily regimen of antiretroviral therapy versus continuation of current anti-retroviral regimen delivered at least twice daily.

antiretroviral therapy
efavirenz
HIV Infection
antiretroviral agents
hiv-1 infection
  • 15 views
  • 07 Nov, 2020
  • 1 location
ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

-emtricitabine/lamivudine-efavirenz first-line regimen. There is evidence to suggest that even in the presence of resistance mutations to tenofovir and lamivudine (K65R or M184V/I), using this backbone

tenofovir
zidovudine
reverse transcriptase inhibitor
efavirenz
antiretroviral agents
  • 61 views
  • 05 May, 2021
  • 2 locations
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG

  • 0 views
  • 27 Jan, 2021
  • 2 locations
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

(namely the TDF and EFV parts). Also, the efavirenz (EFV) component is not compatible for treatment of Hepatitis C (HCV) - which is often also seen in people who have HIV. For these reasons, there is a

  • 19 views
  • 24 Jan, 2021
  • 1 location